130 related articles for article (PubMed ID: 7836866)
1. Intravitreal delivery of ganciclovir in rabbits by transscleral iontophoresis.
Lam TT; Fu J; Chu R; Stojack K; Siew E; Tso MO
J Ocul Pharmacol; 1994; 10(3):571-5. PubMed ID: 7836866
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.
Cheng L; Hostetler KY; Lee J; Koh HJ; Beadle JR; Bessho K; Toyoguchi M; Aldern K; Bovet JM; Freeman WR
Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4138-44. PubMed ID: 15505067
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.
López-Cortés LF; Pastor-Ramos MT; Ruiz-Valderas R; Cordero E; Uceda-Montañés A; Claro-Cala CM; Lucero-Muñoz MJ
Invest Ophthalmol Vis Sci; 2001 Apr; 42(5):1024-8. PubMed ID: 11274081
[TBL] [Abstract][Full Text] [Related]
4. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
Duvvuri S; Janoria KG; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2007 Jun; 23(3):264-74. PubMed ID: 17593010
[TBL] [Abstract][Full Text] [Related]
5. Vitreal pharmacokinetics of biotinylated ganciclovir: role of sodium-dependent multivitamin transporter expressed on retina.
Janoria KG; Boddu SH; Wang Z; Paturi DK; Samanta S; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2009 Feb; 25(1):39-49. PubMed ID: 19232011
[TBL] [Abstract][Full Text] [Related]
6. Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir.
Majumdar S; Kansara V; Mitra AK
J Ocul Pharmacol Ther; 2006 Aug; 22(4):231-41. PubMed ID: 16910863
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the ganciclovir implant in the silicone-filled eye.
Perkins SL; Yang CH; Ashton PA; Jaffe GJ
Retina; 2001; 21(1):10-4. PubMed ID: 11217923
[TBL] [Abstract][Full Text] [Related]
8. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial.
Díaz-Llopis M; Martos MJ; España E; Cervera M; Vila AO; Navea A; Molina FJ; Romero FJ
Doc Ophthalmol; 1992; 82(4):297-305. PubMed ID: 1339115
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis.
Eljarrat-Binstock E; Domb AJ; Orucov F; Frucht-Pery J; Pe'er J
Curr Eye Res; 2007; 32(7-8):639-46. PubMed ID: 17852187
[TBL] [Abstract][Full Text] [Related]
10. Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina.
Kansara V; Hao Y; Mitra AK
J Ocul Pharmacol Ther; 2007 Aug; 23(4):321-34. PubMed ID: 17803430
[TBL] [Abstract][Full Text] [Related]
11. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir.
Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Toyoguchi M; Bergeron-Lynn G; Freeman WR
Invest Ophthalmol Vis Sci; 2002 Feb; 43(2):515-21. PubMed ID: 11818399
[TBL] [Abstract][Full Text] [Related]
12. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis.
Sakurai E; Matsuda Y; Ozeki H; Kunou N; Nakajima K; Ogura Y
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2043-8. PubMed ID: 11481270
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ganciclovir pharmacokinetics in rabbits and man.
Ashton P; Brown JD; Pearson PA; Blandford DL; Smith TJ; Anand R; Nightingale SD; Sanborn GE
J Ocul Pharmacol; 1992; 8(4):343-7. PubMed ID: 1336537
[TBL] [Abstract][Full Text] [Related]
14. Release kinetics of liposome-encapsulated ganciclovir after intravitreal injection in rabbits.
Le Bourlais C; Chevanne F; Ropert P; Bretagne G; Acar L; Zia H; Sado PA; Needham T; Leverge R
J Microencapsul; 1996; 13(4):473-80. PubMed ID: 8808783
[TBL] [Abstract][Full Text] [Related]
15. Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis.
Macha S; Duvvuri S; Mitra AK
Curr Eye Res; 2004 Feb; 28(2):77-84. PubMed ID: 14972713
[TBL] [Abstract][Full Text] [Related]
16. Transscleral iontophoresis of foscarnet.
Sarraf D; Equi RA; Holland GN; Yoshizumi MO; Lee DA
Am J Ophthalmol; 1993 Jun; 115(6):748-54. PubMed ID: 8389526
[TBL] [Abstract][Full Text] [Related]
17. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous.
Li J; Lan B; Li X; Sun S; Lu P; Cheng L
J Control Release; 2016 Dec; 243():78-85. PubMed ID: 27717742
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation.
Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Keefe KS; Bergeron-Lynn G; Severson GM; Soules KA; Mueller AJ; Freeman WR
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1523-32. PubMed ID: 10798672
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal sustained-release ganciclovir.
Smith TJ; Pearson PA; Blandford DL; Brown JD; Goins KA; Hollins JL; Schmeisser ET; Glavinos P; Baldwin LB; Ashton P
Arch Ophthalmol; 1992 Feb; 110(2):255-8. PubMed ID: 1310588
[TBL] [Abstract][Full Text] [Related]
20. Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis.
Macha S; Mitra AK
Drug Metab Dispos; 2002 Jun; 30(6):670-5. PubMed ID: 12019194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
